Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine

Francesco D'Alo', Stefan Hohaus, Manuela Giachelia, Emiliano Fabiani, Nathalie Saulnier, Annalisa Di Ruscio, Francesco Guidi, Maria Teresa Voso, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Abstract

Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.
Lingua originaleEnglish
pagine (da-a)465-471
Numero di pagine7
RivistaLeukemia Research
Volume35
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD29
  • Antigens, CD34
  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Cluster Analysis
  • DNA Methylation
  • Female
  • Gene Expression
  • Gene Expression Profiling
  • Hematopoietic Stem Cells
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes
  • Oligonucleotide Array Sequence Analysis
  • Promoter Regions, Genetic
  • Reverse Transcriptase Polymerase Chain Reaction
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine'. Insieme formano una fingerprint unica.

Cita questo